Obesity & Metabolic Disease Bioanalytical Services
De-Risk Your Obesity & Metabolic Disease Programme with Proven Bioanalytical Expertise
The rapid evolution of obesity and metabolic disease therapies, including GLP-1, amylin and polyagonist programmes, demands more than standard bioanalysis. Clinical development teams now need integrated strategies that address immunogenicity, exposure, tolerability, and differentiation across the clinical lifecycle.
Our obesity and metabolic disease drug development services combine advanced pharmacokinetics (PK), Anti-Drug Antibody (ADA), biomarker, proteomics and data interpretation solutions to help you de-risk programmes and generate evidence from early phase through to pivotal trials.
Obesity trial samples analysed
Biomarker & Bioanalytical Services for Obesity & Metabolic Disease Drug Candidates
Pharmacokinetics
Integrated PK solutions delivering exposure, comparability, and clinical interpretation by connecting pharmacokinetics with immunogenicity and biomarker data.
Immunogenicity/ADA
Integrated immunogenicity solutions treating ADA as a core clinical risk, combining tiered strategies, cross-reactivity assessment, and PK-ADA interpretation for decision-ready insight.
Mechanistic Biomarker Panels
Integrated biomarker strategies designed around organ-system biology to demonstrate how therapies impact tissues, not just weight.
Proteomics
Advanced multiplex proteomics uncovering system-wide biological changes and enabling deeper understanding of treatment effects.
Data Integration & Bioinformatics
Bringing together PK, ADA, biomarker, and clinical data into unified, interpretable outputs for regulatory and commercial success.
Translational Science
Connecting bioanalytical data to clinical outcomes to deliver clear, interpretable outputs to support clinical, translational and regulatory discussions.
Integrated PK/ADA Support for Obesity & Metabolic Disease Drug Programmes
Immunogenicity ADA Strategies
Immunogenicity is not a checkbox – it is central to risk management in obesity drug development. We deliver industry-leading ADA strategies tailored to GLP-1, amylin, and polyagonist therapies:
- Tiered ADA testing: screening, confirmation and titre analysis
- Multi-analyte approaches for combination and fixed-dose products
- Endogenous cross-reactivity assessment
- Neutralising antibody (NAb) strategies
- PK-ADA integration for exposure interpretation
- Hypersensitivity-triggered sampling (IgE, tryptase and more)
- Regulatory-ready data interpretation
Our approach ensures your immunogenicity data supports decision-making, not just reporting.
Integrated PK, ADA and Comparability Strategy
Modern obesity therapies must demonstrate consistency across formulations, devices, and delivery formats. We provide integrated support to:
- Enable bioequivalence and comparability studies
- Assess device and formulation bridging
- Connect ADA data with PK profiles
- Guide risk-based clinical development decisions
This integrated approach aligns with how regulators and sponsors evaluate programmes today.
Mechanistic Organ-System Biomarkers
We implement targeted biomarker panels to deliver mechanistic insight across key domains:
Body Composition & Muscle Preservation: Assess key biomarkers to understand changes in fat distribution, muscle integrity, and overall body composition dynamics:
- Adipokines (leptin, soluble leptin receptor)
- Muscle turnover and inflammation markers
- Support for imaging-based endpoints
Cardiometabolic & Metaflammation Panels: Our panels provide a comprehensive view of cardiometabolic health and low-grade systemic inflammation:
- hsCRP, lipids and free fatty acids
- Renal markers (UACR, eGFR, cystatin C)
- Glucose and insulin metabolism
Tolerability & Hypersensitivity Biology: We evaluate immune responses to therapy to better understand safety, tolerability, and adverse reactions:
- Drug-specific and total IgE
- Tryptase and event-triggered sampling
- Injection-site and systemic response analysis
Multi-omics & Discovery: We combine advanced proteomics and metabolomics capabilities with expert biological interpretation, turning data into actionable insight.
Partner with a CRO that
Understands Obesity & Metabolic Disease Programmes
Build a Complete Differentiation Story for Your Obesity Drug Asset
- Demonstrate muscle preservation and quality of weight loss
- Show improvements in liver and cardio-renal risk
- Quantify reductions in inflammatory burden
- Identify early safety and tolerability signals
- Build a compelling, data-driven differentiation story
7
Years supporting obesity clinical trials
50,000+
Obesity clinical samples analysed
100,000+
Analyses run on obesity clinical samples
Improving the quality of human health.
Contact Us
Let’s discuss solutions to advancing your obesity/metabolic disease drug candidates.
